{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:32:54Z","timestamp":1769387574098,"version":"3.49.0"},"reference-count":17,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Standard systemic treatment has not been established for refractory meningioma. This retrospective study aimed to identify prognostic factors for overall survival and document outcomes of systemic therapies. We reviewed patients with meningioma followed at CHUM hospital between 2006 and 2022. Only patients with progression after first-line treatment were included. Among 750 patients, 107 (14%) experienced progression after first-line treatment. They were divided into two groups: Group 1 (n = 69, 64%) received salvage local treatments, and Group 2 (n = 38, 36%) received additional salvage systemic treatments. The median follow-up time from diagnosis was 7.5 years. 10-year OS was 88.3% (Group 1) vs. 67.2% (Group 2) (p = 0.009). Mean survival after stopping systemic treatment was 8.94 months. Key prognostic factors for poorer survival included age \u2265 65 (HR = 2.82; p = 0.009), WHO grade 2 or 3 (HR = 4.25; p = 0.004), and progression after second-line treatment (HR = 4.77; p = 0.004). Bevacizumab was associated with a mPFS of 12 months and 1-year OS of 64,6%, whereas non-Bevacizumab treatments\u2014including Hydroxyurea, Somatostatin, and Sunitinib\u2014were associated with a mPFS of 7 months and 1-year OS of 52,6%. This study highlights the fatal nature of recurrent meningiomas and the urgent need for systemic treatments that can improve their survival.<\/jats:p>","DOI":"10.3390\/curroncol32090516","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T05:59:51Z","timestamp":1758088791000},"page":"516","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Retrospective Study on Prognostic Factors and Systemic Treatments of Refractory Meningiomas"],"prefix":"10.3390","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-1447-5195","authenticated-orcid":false,"given":"Dan-Thanh Christine","family":"Nguyen","sequence":"first","affiliation":[{"name":"Department of Hematology-Oncology, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H2X 1R6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cyril","family":"Nader","sequence":"additional","affiliation":[{"name":"Department of Anesthesia, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H2X 1R6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl","family":"B\u00e9langer","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H2X 1R6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7363-7382","authenticated-orcid":false,"given":"Sarah","family":"Lapointe","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H2X 1R6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Lemieux","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H2X 1R6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c9milie","family":"Lemieux-Blanchard","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H2X 1R6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Paul","family":"Bahary","sequence":"additional","affiliation":[{"name":"Department of Radio-Oncology, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H2X 1R6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Masucci","sequence":"additional","affiliation":[{"name":"Department of Radio-Oncology, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H2X 1R6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carole","family":"Lambert","sequence":"additional","affiliation":[{"name":"Department of Radio-Oncology, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H2X 1R6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8747-648X","authenticated-orcid":false,"given":"David","family":"Roberge","sequence":"additional","affiliation":[{"name":"Department of Radio-Oncology, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H2X 1R6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Moumdjian","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H2X 1R6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moujahed","family":"Labidi","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H2X 1R6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2745-2704","authenticated-orcid":false,"given":"Romain","family":"Cayrol","sequence":"additional","affiliation":[{"name":"Department of Pathology, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H2X 1R6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Florescu","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H2X 1R6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noad149","article-title":"CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016\u20132020","volume":"25","author":"Ostrom","year":"2023","journal-title":"Neuro Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"i5","DOI":"10.1093\/noajnl\/vdad020","article-title":"The joint impacts of sex and race\/ethnicity on incidence of grade 1 versus grades 2\u20133 meningioma across the lifespan","volume":"5","author":"Walsh","year":"2023","journal-title":"Neuro-Oncology Adv."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.2217\/fon-2018-0006","article-title":"An overview of meningiomas","volume":"14","author":"Buerki","year":"2018","journal-title":"Future Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e718","DOI":"10.1016\/j.wneu.2021.04.138","article-title":"Risk Factors for High-Grade Meningioma in Brain and Spine: Systematic Review and Meta-analysis","volume":"151","author":"Shin","year":"2021","journal-title":"World Neurosurg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.revmed.2021.06.011","article-title":"Meningiomas: A review of current knowledge","volume":"43","author":"Boetto","year":"2022","journal-title":"Rev. Med. Interne."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/neuonc\/noab150","article-title":"EANO guideline on the diagnosis and management of meningiomas","volume":"23","author":"Goldbrunner","year":"2021","journal-title":"Neuro-Oncology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1200\/JCO.23.01059","article-title":"RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults","volume":"41","author":"Wen","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"vdac123","DOI":"10.1093\/noajnl\/vdac123","article-title":"A multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma","volume":"4","author":"Kumthekar","year":"2022","journal-title":"Neuro-Oncology Adv."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11060-012-0861-0","article-title":"Bevacizumab therapy for adults with recurrent\/progressive meningioma: A retrospective series","volume":"109","author":"Lou","year":"2012","journal-title":"J. Neuro-Oncology"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Nunes, F.P., Merker, V.L., Jennings, D., Caruso, P.A., di Tomaso, E., Muzikansky, A., Barker, F.G., Stemmer-Rachamimov, A., Plotkin, S.R., and Pieper, R.O. (2013). Bevacizumab Treatment for Meningiomas in NF2: A Retrospective Analysis of 15 Patients. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0059941"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1200\/jco.2009.27.15_suppl.2063","article-title":"Phase II study of hydroxyurea for unresectable meningioma (Southwest Oncology Group S9811)","volume":"27","author":"Swinnen","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11060-011-0741-z","article-title":"Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma","volume":"107","author":"Chamberlain","year":"2011","journal-title":"J. Neuro-Oncology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1212\/01.wnl.0000271382.62776.b7","article-title":"Recurrent meningioma: Salvage therapy with long-acting somatostatin analogue","volume":"69","author":"Chamberlain","year":"2007","journal-title":"Neurology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/neuonc\/nou148","article-title":"Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma","volume":"17","author":"Kaley","year":"2015","journal-title":"Neuro-Oncology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1158\/1078-0432.CCR-19-2109","article-title":"Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial","volume":"26","author":"Graillon","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1007\/s00701-022-05301-y","article-title":"The WHO 2021 Classification of Central Nervous System tumours: A practical update on what neurosurgeons need to know\u2014A minireview","volume":"164","author":"Torp","year":"2022","journal-title":"Acta Neurochir."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1038\/s41591-024-03167-4","article-title":"Molecular classification to refine surgical and radiotherapeutic decision-making in meningioma","volume":"30","author":"Wang","year":"2024","journal-title":"Nat. Med."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/9\/516\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:46:45Z","timestamp":1760035605000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/9\/516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,16]]},"references-count":17,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["curroncol32090516"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32090516","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,16]]}}}